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Thromboxane synthase (CYP5A1) is a membrane-bound cytochrome P450. It synthesizes 
thromboxane A2 (TXA2) from PGH2, which is a potent mediator of platelet aggregation and 
vasoconstriction. TXA2 has been implicated in a wide range of pathophysiological disease 
conditions. Though it is a membrane protein, most of its biochemical characterization has been 
performed in soluble reconstituted systems. Membranes have been shown to play an 
important role in the structure and function of membrane proteins. This work presents the first 
report on membrane incorporated CYP5A1 and its biochemical characterization. To achieve 
this, native-like lipid bilayers called nanodiscs were used to obtain monomeric and stabilized 
protein. The protein was successfully expressed in a bacterial expression system and the 
purified protein was incorporated into nanodiscs. This system was functionally characterized 
using CO binding, substrate binding and activity assays. The specific activity of the protein was 
evaluated both in nanodiscs and detergent solubilized system and was shown to increase by 
100% in Nanodiscs. In order to understand the role of the membrane in modulating the 
electrostatic environment of the protein, redox potentials of substrate free and substrate 
bound CYP5A1 in membranes was measured. This is also the first account of an endoperoxide 
substrate like PGH2 bound to a protein. We noticed that the redox potential of the protein in 
Nanodiscs were not very different from those in detergents showing lack of modulation of the 
active site electrostatics by the membrane environment. The kinetics of substrate analog 
(U44069 and U46619) and cyanide binding to CYP5A1-nanodiscs was measured using stopped 
flow to evaluate the conformational change in the protein in lipid bilayers of Nanodiscs. It was 
determined that the kinetic parameters of binding of the substrate analogs to CYP5A1-nanodisc 
system were different from detergent solubilized state. Moreover, the accessibility of cyanide 
to the active site of the protein also changed in CYP5A1-nanodiscs as compared to detergent 
solubilized systems. These results show that the conformation of CYP5A1 is different in 
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CHAPTER 1: INTRODUCTION TO THROMBOXANE SYNTHASE 
Thromboxane synthase (CYP5A1) is an endoplasmic reticulum membrane protein that 
belongs to the cytochrome P450 superfamily of enzymes. In general, cytochrome P450 
enzymes are mono-oxygenases that catalyze reactions involved in drug metabolism, 
synthesis of cholesterol, steroids and many other lipids. CYP5A1 is highly expressed in the 
lung, platelets, kidney, stomach, duodenum, colon and spleen. CYP5A1 is mainly known for its 
function in platelets and is involved in the production of Thromboxane A2 (TXA2). TXA2 is a 
biologically active metabolite of arachidonic acid, which is a ω-6 fatty acid found in diet (Figure 1.1). 
It is formed from the prostaglandin H2 (PGH2) by the action of CYP5A1. CYP5A1 expression has been 
found to be closely associated with inflammatory diseases. It is widely implicated in a range of 
disease conditions like cardiovascular disease, arthritis, cancer and many others due to its effects in 
promoting platelet aggregation and vasoconstriction. A wide variety of human cancers have found 
increased expression of cyclooxygenase (COX) in corresponding tissues thereby increasing interest in 
its downstream metabolites like TXA2.  
       
1.1 Pharmaceutical potential of CYP5A1 
Thromboxane synthase catalyzes the isomerization of PGH2 to the chemically unstable 
metabolite, TXA2. TXA2 is a potent inducer of vasoconstriction and platelet aggregation. 
There has been development of thromboxane synthase inhibitors and TXA2 receptor 
antagonists as TXA2 has been associated with various cardiovascular and pulmonary disease 
conditions. Its key role as a platelet activator and aggregator has been implicated in 
cardiovascular conditions like unstable angina, stroke and progression of ischemic injury 
after coronary artery occlusion. In other intestinal, renal and pulmonary tissues, it has been 
shown to affect blood flow distribution and airway caliber. Release of TXA2 in excess in 
these tissues has been shown to initiate ulcer, pulmonary hypertension, renal and 
bronchoconstriction. It has also been linked to pregnancy complications causing conditions 
like preeclampsia resulting in reduced uteroplacental blood and premature delivery (1, 2). 
The evidence for the existence of an endoperoxide structure for the formation of 
prostaglandins was discovered as early as 1965, though it was not until 1973 that PGH2 was 
isolated. These endoperoxides were then seen to have distinctive effects on platelets and 
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smooth muscle contractions and were later classified as a new group of compounds called 
thromboxanes. TXA2 was then detected and implicated in the contraction of porcine 
coronary arteries due to thrombin-stimulated platelets. TXA2 was found to be an immediate 
response of activated platelets and that the release was complete in 15 seconds.  Intensive 
research has been ongoing in this area to elucidate the biochemistry, physiology and 
pharmacology of these compounds (3). 
Role in Hypertension: Studies with inhibitors of thromboxane synthase have suggested 
a possible role of thromboxane synthase in increasing blood pressure in spontaneously 
hypertensive rats. Thromboxane B2, which is a stable hydrolysis product of TXA2 was 
measured in both the serum of whole blood and platelet enriched blood in experimental 
and control rats. Severe hypertension was seen to develop in rats with prior vascular 
damage leading to speculations that TXA2 played an important role (4). Severely 
hypertensive rats were found to contain platelets with low survival, which when injected 
into stroke resistant spontaneously hypertensive (SRSH) rats showed normal survival 
patterns. This study suggested that the low platelet survival was due to vascular 
abnormalities. Injection of a thromboxane synthase inhibitor UK 38485 resulted in delaying 
severe hypertension in the experimental rats but did not prevent stroke. Therefore TXA2 
was shown to have a role in elevating the blood pressure but its sole inhibition did not 
prevent a stroke from occurring.  
Role in Coronary artery disease: Formation of TXA2 in unstimulated monocytes from 
patients with unstable angina, stable effort angina and control was studied to examine the 
role of TXA2 in the occurrence of myocardial ischemia (5, 6). It was found that samples from 
patients with unstable angina have a higher concentration of TXA2 than those with effort 
angina or controls. CYP5A1 inhibitor and TXA2 receptor antagonist picotimide was found to 
be more effective in reducing the number of angina attacks, silent ischemic episodes and 
duration of ischemia even though it had a lower effect on the inhibition of TXA2 formation 
in circulating monocytes than aspirin. Therefore TXA2 formed by monocytes has been 
shown to have a significant role in the development of myocardial ischemia in patients with 
unstable angina.  
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Role in Thrombolysis: During coronary thrombolysis, a marked increase in platelet 
activation was seen which decreased the response of patients to thrombolytic therapy (7). 
Coronary thrombolysis is mainly used for the treatment of patients with acute Q wave 
myocardial infarcts. The main problems facing this therapy include the time required for the 
thrombolysis and re-occlusion of the artery after therapy. Inhibition of TXA2 by aspirin or 
other combinations of drugs led to accelerated reperfusion and less cyclic flow variations. 
To test whether thrombin induced acute re-occlusion of infarct related arteries, argatroban, 
which is a thrombin inhibitor, was used on canine thrombolysis models. Increase in 
thromboxane B2 were observed after reperfusion by the thrombin inhibitor. Therefore 
response to thrombin inhibitors was weakened by TXA2 formation. This problem was again 
countered with the use of a TXA2 inhibitor in combination with the thrombin inhibitors.  
Tissue type plasminogen activator is usually used for patients with acute myocardial 
infarction (8). Using this technique, reperfusion was seen to be followed by gradual cycles of 
occlusions followed by blood flow until a persistent occlusion occurred.  TXA2 and serotonin 
receptor antagonists in combination were found to prevent re-occlusions throughout 
experimental times. 
Role in Preeclampsia: Preeclampsia is caused due to an imbalance between prostacyclin 
synthase and TXA2. Plasma levels of prostacyclin and thromboxane were determined in 
normal, mild preeclampsic and severe preeclampsic pregnancies (9, 10). Normal 
pregnancies were seen to favor a higher prostacyclin to thromboxane ratio. The ratio was 
decreased slightly in mild preeclampsia and to a greater extent in severe preeclampsia. In 
both mild and severe preeclampsia, it was found that the prostacyclin levels were 
decreased to the same extent, but only in the severe cases was thromboxane shown to 
increase significantly. 
 
1.2 Review of Mechanism of action 
CYP5A1 along with Prostacyclin synthase (PGIS) belongs to a class of compounds called 
prostanoids, which are a family of key signaling molecules. They play a role in inflammation, 
autoimmune disorders, shock syndromes, physiologic regulation like growth and 
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differentiation. As these enzymes are synthesized and released on demand, they are subject 
to rapid formation and degradation making them difficult to study. CYP5A1 is considered a 
non-classical cytochrome P450. The classical cytochrome P450 enzymes are 
monooxygenases that are involved in drug metabolism and synthesis of cholesterol, steroids 
and other lipids. CYP5A1 is considered a non-classical cytochrome P450 in the sense that it 
does not need an electron donor to catalyze its reaction. It catalyzes its reaction by 
isomerization of its substrate. 
Structural Studies: Nucleotide sequence of human platelet cDNA was used to deduce 
the primary structure of CYP5A1. It is a 533 amino acid long chain with a molecular weight 
of 60487 Da. It only exhibits a maximum of 40% homologous identity with the rest of the 
P450s. It still has the highly conserved cysteine residue near the heme binding site of P450s 
was found at residues 472-492 (11). The mutant form of the protein where the cysteine was 
replaced by a serine was found to be inactive, though it was expressed at the same level 
(12). The gene expresses two transcript variants named TXS I and TXS II. TXS II was found to 
contain a 163 bp deletion at the cysteine containing peptide sequence during alternate 
splicing thus rendering it non-functional (13). Both forms of this enzyme were found to be 
present in different organs of the body. Thus this was concluded to be part of a regulatory 
mechanism to limit production of CYP5A1.  Mutations in the residues, Asn-110, Trp-133, 
Arg-137, Arg-413, and Arg-478 were found to affect the heme binding of the protein and 
also reduced the enzymatic activity down to 5% of the wild type (14). The mutated proteins 
also lost their ability to bind substrate analogs and were more prone to digestion by 
proteases. Based on a few similarities to P450 terp, it was predicted that the A ring 
propionate in CYP5A1 was hydrogen bonded to Asn-110, Arg-413, and Arg-478 and the D 
ring propionate to Trp-133 and Arg-137. 
Polymorphisms: The human CYP5A1 was found to contain 13 exons over a 150 kb range. 
The haploid human genome contained only one transcript of the CYP5A1 gene. 
Transcription of this gene was found to be mainly TATA dependent though it has multiple 
start points for transcription. The ninth exon of the gene contained a repetitive dinucleotide 
CA sequence that exhibited allelic polymorphisms (15). 
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Expression of soluble form: Though CYP5A1’s pharmaceutical potential has been 
identified; its reaction mechanism has not yet been extensively studied. This is primarily due 
to its tendency to aggregate and oligomerize in solution.  
In order to better understand the mechanism of this protein, it has been purified in 
bacterial expressions systems. From the hydropathy plot of the protein sequence, the 
hydrophilic and hydrophobic residue profile was obtained. Using this plot the major 
transmembrane regions in the N-terminal region of the gene could be determined and 
modified to include more hydrophilic peptide sequences. A hydrophilic sequence, MAKKTSS 
was added to replace the major hydrophobic transmembrane region (16). 
Characterization of recombinant CYP5A1: The modified CYP5A1 showed a typical Soret 
peak at 416 nm and purified modCYP5A1/2C5-his exhibited an absorption spectrum 
consistent with a low-spin P450, with a Soret peak at 416 nm and α and β bands at 567 and 
534 nm, respectively. The dithionite-reduced protein with carbon monoxide bound showed 
a major peak at 450 nm and a shoulder at 420 nm which was eliminated in the difference 
spectra. This indicated that the heme was incorporated in the modified protein without any 
structural perturbation (17).   
A coupled assay was also performed to determine whether PGH2 would be converted to 
MDA and HHT. Formation of HHT and MDA, as indicated by the absorption maxima at 234 
and 268 nm, respectively, was observed in the presence, but not in the absence, of the 
chimeric protein. The formation of reaction products TXB2, MDA and HHT were monitored 
to assess their stoichiometry. The products were found in a molar ratio of 1.0:1.0:1.0 similar 
to the wild type CYP5A1. Km and Vmax were found to be 32.9 ± 5.5 μM and 2.33 ± 0.37 μmol 
MDA/min/mg of protein compared to the wild type CYP5A1 which had a Km of 22.5 ± 4.5 μM 
and a Vmax of 35.1 ± 3.2 μmol MDA/min/mg of protein. To assess the binding characteristics 
of the modified protein, absorption spectra of different substrate analogs and inhibitors 
were monitored. As expected, binding of substrate analogs showed a blue shift in the Soret 
peak and that of inhibitors showed a red shift. The dissociation constant of U44069 was 16 
μM, close to that of wild type, 21 μM. 
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Mechanism hypothesis: CYP5A1 catalyzes approximately equal amounts of two distinct 
reactions when reacted with its substrate PGH2. 
 
 
Mechanism 1: TXA2 is the biologically active compound that is rapidly converted to its 
biologically inactive form, TXB2. It is a potent vasoconstrictor and inducer of platelet 
aggregation. The first reaction occurs through the isomerization of PGH2. The second 
reaction is a fragmentation reaction which results in the formation of 12-l-hydroxy-5, 8, 10-
heptadecatrienoic acid (HHT) and malondialdehyde (MDA). The biological functions of MDA 
and HHT are still unclear, though MDA has been found to form adducts with amino groups 
of proteins and DNA which have been detected in atherosclerotic lesions of human aorta. 
These products are formed in a 1:1:1 (TXA2: MDA: HHT) ratio. Different mechanisms have 
been tried to justify the formation of these products. The initial reaction starts from 
arachidonic acid and from it the formation of PGH2. PGH2 contains a relatively weak epidioxy 
bond which is the reaction center for the initiation of all subsequent steps. It can be cleaved 
in different ways to yield a total of five different products (18).  Two of the products, PGD2 
and PGE2 are formed by the heterolytic cleavage of the epidioxy bond. Formation of TXA2 is 
more complex. Heme thiolate ligands were suggested to be involved because of their ability 
to transfer electrons from peroxides to organic compounds (19).  To elucidate the 
characteristics of substrate binding and catalytic mechanisms of the heme moiety, different 
substrates and inhibitors were bound to the protein and their absorption spectra studied.  
The addition of substrate did not convert the Fe (III) into a high spin complex as would be 
expected with other P450s. It was postulated that the epidioxy ligand replaced the water 
ligand at the sixth coordination center and hence only subtle spectral changes could be 
observed through substrate binding. From inhibitor binding studies, it was concluded that 
the substrate bound to the Fe center through its epidioxy bridge and the side chain was 
above the heme plane at an angle. 
Ortho substituted inhibitors did form a high coordination, high spin shift to 390 nm 
which could have been due to steric hindrance and displacing of the endogenous water 
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ligand at the sixth coordination site. The mechanism proposed by Hecker and Ullrich uses 
radical intermediates to explain the reaction. From EPR and other optical studies, it was 
concluded that CYP5A1 reacts with the C-9 oxygen of the endoperoxide bond.  Oxy radicals 
are formed first, which are then rearranged to carbon radicals. These could then rapidly be 
converted into carbocations by the ferrylthiolate or iron (III) thiyl structures formed as 
intermediates . 
CYP5A1 also converts PGH3 into TXA3 but interestingly cannot convert PGH1 into TXA1. It 
rather converts them into HHT and MDA. Other compounds like PGG2, 8-iso-PGH2, 13(S)-
hydroxy-PGH2, and 15-keto-PGH2 were also applied to test its substrate specificity. CYP5A1 
converted PGH1, 8-iso-PGH2, 13(S)-hydroxy-PGH2 and 15-keto-PGH2 into the corresponding 
heptadecanoic acid (C17) and MDA, whereas the corresponding thromboxane derivative was 
formed only from PGG2, PGH2, and PGH3 together with the corresponding C17 metabolite 
and malondialdehyde in a 1:1:1 ratio. This led to the suggestion that HHT was formed 
through a common intermediate for all these reactions. The endoperoxide bond is cleaved 
first followed by the rapid formation of [S- . . . Fe'". . . O-R] species which gives rise to an 
alkoxy radical. The next step was found to be a β-scission pathway through isotope studies, 
which showed that the C-H bond at the C-12 position was not cleaved during this synthesis. 
This radical intermediate could then follow one of two steps leading to the formation of 
TXA2 or MDA and HHT. The intermediate when decomposed, formed MDA and HHT or 
undergoes a Fe (IV) oxidation reaction to form a carbocation and finally rearrange to form 
TXA2. Use of other substrates further validated their model. The 15-keto group in 
conjugation with the double bond at C-13 position destabilized the C-12 radical intermediate 
leading to the production of only MDA and HHT, the fragmentation products. The shifting of 
the double bond to 14-15 position and hydroxyl group to C-13 position remarkably 
decreased all reactions. The alkoxy radical undergoes a β-scission and subsequent ionic 
rearrangement to form TXA2. Therefore homolytic cleavage of the endoperoxide bond forms 
Cpd II with the alkoxy radical whereas heterolytic cleavage forms Cpd I which is either a 




ROOH + Fe (III) → RO  + Fe (IV) O 
 
Mechanism 2: In this mechanism proposed by Yanai and Mori (19) the pathway proceeds 
through the formation of Fe (III)-П cation radical intermediates. Density functional studies 
were performed to reveal that the Fe (III) porphyrin system reduced the activation energy of 
the endoperoxide bond cleavage by 34 kJ/mol. The endoperoxide C (9) oxygen atom 
attaches to the Fe(III) active site of the porphyrin and an alkoxy radical intermediate is 
formed by homolytic cleavage. An allyl radical is then formed by the cleavage of C (11)-C 
(12) bond and a one electron transfer of the 6 membered ring leads to the formation of 
TXA2. A Fe (III) or any metal containing catalysts with one electron acceptor ability can lead 
to the formation of TXA2. 
Reactive intermediates: The binding of CYP5A1 with its substrate analog U44069 is a 
two-step binding process which gives a Kd value of 28 μM (20). Similarly binding of nitrogen 
based ligands like Imidazole and Clotrimazole also follow this two-step binding process 
where the Kobs of the fast phase is linearly dependent on the concentration of substrate or 
inhibitor and that of the slow phase is independent of the concentration. Rapid scan 
stopped flow analysis or freeze quench EPR spectroscopic studies failed to reveal the radical 
intermediates formed. The reaction of CYP5A1 metabolism was then concluded to be very 
rapid with no or little accumulation of products. CYP5A1 transforms 15-HPETE to 13-OH-14, 
15 -EET and also to 15-ketoeicosatetraenoic acid (15-KETE) and 15-hydroxyeicosatetraenoic 
acid (15-HETE) (11). Homolytic scission leads to the formation of 13-OH-14, 15 -EET and 15-
KETE, whereas heterolytic scission is needed for the formation of 15-HETE. 60% of the 15-
HPETE added was homolytically cleaved by CYP5A1. Homolytic cleavage was 1.4 times faster 
than heterolytic cleavage by CYP5A1. 
The intermediates formed from this reaction were investigated using rapid scan stopped 
flow. The spectral changes observed show that there are two reactive intermediates, one 
with a blue shifted soret peak (species B) and is a CYP5A1-15-HPETE complex and the other 
one species C, which was postulated to be a mixture of Cpd I and Cpd II.   
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Active site characteristics: To determine the conformational changes and 3D structure of 
PGH2 in the active site of CYP5A1, a high resolution NMR spectroscopy of its substrate 
analog U44069 was performed. From these experiments, it was found that the triangle 
shape of the free U44069 was changed to a more compact structure when it was in the 
bound state (21). The active site of CYP5A1 could fit the compact structure of the substrate 
analog but not its free form. This shows that PGH2 also undergoes some structural change 
when it binds to CYP5A1. 
CYP5A1 coordination with PGH2 substrate analogs U44069 and U46619 showed a few 
interesting results (22).  Coordination with U44069 was found to be in a 6-coordinate low 
spin state in accordance with previous studies, while those with U46619 showed results 
contrary to previous studies, indicating that it too was in a 6-coordinate low spin complex 
rather than a 5 coordinate high spin state (23). Main vibrational peaks at 1374, 1503, 1564, 
1587 and 1638 cm-1 were seen for CYP5A1 using high-frequency Raman resonance 
spectroscopy. Addition of both U44069 and U46619 did not alter these vibrational modes to 
a significant extent. Hence CYP5A1 when bound to these substrate analogues was found to 
be in a 6c/ls state as opposed to the 5c/hs state proposed earlier for U46619 based on 
absorption spectra. Earlier mechanisms favoring binding of the O (9) oxygen of U44069 over 
that of O (11) of U46619 to CYP5A1 were questioned in light of this new evidence. Although 
U46619 was shown to be more flexible and prone to alter the protein environment 
compared to U44069.  
Based on the structural similarity to P450cam, the heme pocket in the active site was 
seen to have two propionate groups that interact with the protein matrix. The resting 
enzyme shows one main propionate bending mode, while the addition of substrate analogs 
increases a second propionate bending mode and decreases the intensity of the first one. 
Based on different vibrations seen for the substrate analogs, U44069 with the O (9) binding 
was postulated to disrupt the 6-propionate group due to its carboxylate side chain. U46619 
on the other hand, due to a different orientation did not interact with the propionate groups 
with its carboxylate side chain but did disrupt the hydrogen bonding network of the 
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CHAPTER 2: ELUCIDATING THE ROLE OF MEMBRANES IN MODULATING THE 
THERMODYNAMICS AND KINETICS OF SUBSTRATE BINDING TO THROMBOXANE 
SYNTHASE 
 
2.1 Effect of membranes on proteins in general 
While CYP5A1 is an endoplasmic reticulum membrane protein (24), all of its analyses to 
date have been performed in soluble reconstituted systems. The enzyme being catalytically 
competent in these systems, they have provided great insight into the mechanism and 
function of this protein. Though the complex conditions of the cell membrane environment 
cannot be mimicked, recent advances in technology have made possible the study of 
membrane proteins in lipid bilayers that come closer to the natural environment of the 
proteins in question. These studies have proven necessary due to effects the lipid 
composition and state of the bilayer can have in modulating enzyme activity (25-27) . The 
presence of specific types of phospholipids has also been hypothesized to stabilize 
kinetically distinguishable conformations of cytochrome P450s, and modulate their affinities 
for substrates.  
In addition to the differences in the composition, lipid bilayers are also known to be 
complex systems in a dynamic state with lateral, rotational, and transverse movements 
(28). The bilayer exposes the proteins to different regions of hydrophobicity while travelling 
transversely through it. The composition of lipids in a membrane has been shown to play an 
important role in fluidity of the membrane (29). This membrane fluidity in turn affects the 
activation energy of enzyme function (30). For example, the activity of CYP3A4 can be 
modulated by the presence of anionic lipids and the biophysical characteristics of CYP3A4 
change in lipid bilayers (31). The protein displays monophasic reduction kinetics as opposed 
to multiphasic kinetics in detergents. And many membrane proteins also need specific 
anionic or cationic lipids for their function. Like the integral membrane protein tissue factor 
which requires acidic phospholipids to recruit a soluble factor VIIa necessary for the 
initiation of a blood coagulation cascade(32). Therefore to account for the effect of 
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membranes on CYP5A1 in its native-like environment and to understand the role of this 
microenvironment on CYP5A1 function, we have incorporated CYP5A1 into lipid bilayers of 
Nanodiscs. As a first step we use CYP5A1-Nanodiscs to measure the activity of CYP5A1 in 
neutral lipids. This initial study will elucidate the importance of lipids in modulating the 
activity of CYP5A1. 
 
2.2 Model lipid bilayers of Nanodisc for functional interrogation of CYP5A1 
In this study we used Nanodiscs to biochemically elucidate the function of CYP5A1 in 
lipid bilayers. Nanodiscs are essentially lipid bilayers held together with the help of 
membrane scaffold proteins (33). Incorporating a CYP protein into Nanodiscs mimics the 
endogenous membrane environment of the protein (34). Nanodiscs have been proven to be 
excellent for the solubilization and biochemical investigation of many diverse membrane 
protein systems including G-protein coupled receptors (GPCRs). Moreover, this technology 
has enabled the stabilization of membrane proteins both in solution (35-39) and on surfaces 
(38, 40-43).  
 
2.3 Composition of platelet membranes 
A selective increase in thromboxane synthase activity has been found in the intracellular 
membrane elements of platelets, known as dense tubular membranes (24). These changes 
in activity have been suggested to be due to differences in lipid composition of the inner 
and surface membranes of platelets (44). An analysis of four glycerophospholipids: 
phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine (PS), and 
phosphatidylcholine (PC), found in membranes, shows that the inner platelet membranes 
are enriched in PC and PI, PS remained constant, while PE is decreased when compared to 
the surface membrane.  Inner membranes of platelets also appear to be depleted of 
sphingomyelin in comparison to the outer surface membrane. This enrichment of 
thromboxane synthase activity associated with blood platelet inner membranes may be 
attributed to the differences in lipid composition. 
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Even though the pharmaceutical potential of this protein has been well established, its 
mechanism yet remains to be characterized. This is mainly due to it being a transmembrane 
protein causing it to aggregate in solution. Recently nano-scale lipid like bilayers called 
Nanodiscs has been developed by Sligar lab, which will be used here to incorporate and 
solubilize the protein. The functional properties of the protein can then be investigated in 
vitro through biophysical assays. The chemical mechanisms of this enzyme can play a 
significant role in developing therapeutics and unraveling the nature of inflammatory 
disease conditions in the human body.  
 
2.4 Materials and methods 
Materials: Human CYP5A1 gene was obtained from Origene. The bacterial strain DH5α 
was obtained from Invitrogen. Ampicillin, arabinose, chloramphenicol, IPTG and Ni-NTA 
resin were bought from Gold Biotechnology. δ-Aminolevulinic acid and hematin were 
obtained from Frontier Scientific. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) 
was purchased from Avanti Polar Lipids, Inc.  Amberlite XAD 2 was acquired from Supelco.  
Arachidonic acid, PGB2, TXB2, U44069 and U46619 were obtained from Cayman Chemicals. 
COX-2 was kindly provided by Ben Orlando and Dr. Michael Malkowski. All other chemicals 
were purchased from Sigma-Aldrich or Fisher Chemicals.   
Gene modification: Two modifications were made to the CYP5A1 human gene, which 
was obtained from Origene. For the first construct, the gene was N-terminus modified and a 
truncation of 1-29 amino acids was made. There is an N-terminus insert MALLAVF in its 
place which favors expression in E.coli and also a His-tag at the C-terminus. An NdeI and 
XbaI site have been engineered at the N-terminus and C-terminus respectively. The 
modified gene is in pAr5 (modified pCWori) which has an N-terminus NdeI site. pTGro7 + 
pGroE are co-transformed with the modified gene into DH5alphaF’1Q Max Efficiency cell 
line. The co-transformed cell has both ampicillin and chloroamphenicol resistance. For the 
second construct, the first 1-29 amino acids of the human CYP5A1 gene were truncated and 
replaced with the hydrophilic MAKKTSS sequence along with an addition of a histidine tag at 
the C terminus to aid in purification (45). 
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Expression and purification of CYP5A1: The first 1-29 amino acids of the human 
CYP5A1 gene were truncated and replaced with the hydrophilic MAKKTSS sequence along 
with an addition of a histidine tag at the C terminus to aid in purification (45). The construct 
was inserted into a pCWori vector and co-transformed with pTGro7 (chaperonin system) 
into DH5α cells. The recombinant CYP5A1 construct was expressed and purified according 
to published protocols with certain modifications (46). Briefly, the cells were grown in 
terrific Broth (TB) media until they reached an O.D. of 0.8-1.0 and were induced with 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) and 0.5 mM delta-aminolevulinic acid (δ-ALA) 
and 4 mg/L arabinose. They were grown for 44 hours at 26°C and 160 rpm. The harvested 
cells were resuspended in Buffer A (0.1 M potassium phosphate pH 7.4, 10% glycerol, 0.1 M 
sodium chloride) containing 2 mM magnesium chloride, 1 mM 
phenylmethanesulfonylfluoride (PMSF), approximately 1 mg each of D’Nase and R’Nase for 
1 hour and lysed 5 times using a 1/8’ tip Heat Systems Ultrasonics (Qsonica, Newtown, CT) 
sonicator at 80% duty cycle with 1 minute rest between cycles. The solution was then 
centrifuged using a Beckman ultracentrifuge (Beckman Coulter, Brea, CA) at 35K rpm for 1 
hour and the pellet was resuspended in Buffer A containing 2% Lubrol overnight to 
solubilize CYP5A1. The sample was again centrifuged at 35K rpm for 1 hour before loading 
the supernatant onto a Ni-NTA column pre-equilibrated with Buffer A. The column was first 
washed with 3X column volumes of Buffer A containing 2% Lubrol and then incubated with 
5X column volume of buffer B (0.1 M potassium phosphate, 10% Glycerol, 0.2% Lubrol) 
containing 10 mM Histidine, 5 mM ATP, 10 mM MgCl2 and 150 mM KCl to separate any co-
purifying GroEL for 2 hours. CYP5A1 was then eluted using 0.1 M potassium phosphate, 10% 
Glycerol, 0.1 M NaCl, 0.2% Lubrol containing 100 mM Histidine.  
Assembly of CYP5A1-Nanodiscs: CYP5A1-Nanodiscs were assembled from a mixture of 
CYP5A1, membrane scaffold protein (MSP) and POPC lipids by removing the detergent using 
Amberlite (47). Membrane scaffold protein (MSP1D1) has a Histidine tag preceded by a 
highly specific Tobacco Etch Virus (TEV) protease recognition site. The Histidine-tag was 
cleaved from the protein using TEV protease and is referred to as MSP1D1 (-). POPC lipids 
stock concentration was determined by phosphate analysis. Small aliquots of lipids were 
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dried using nitrogen gas to remove residual chloroform and were solubilized using 100 mM 
sodium cholate. MSP1D1 (-) was added in a ratio of 65:1 (lipids: MSP (-)) and the solution 
incubated at 4oC for 1 hour on a shaker. Detergent solubilized CYP5A1 was then added in a 
ratio of 15:1 (CYP5A1: MSP (-)) and incubated for a further of 1 hour. Biobeads were added 
to the final mixture and left overnight to remove detergent and initiate the formation of the 
Nanodiscs. After addition of the biobeads and overnight incubation, the lipids: MSP (-): 
protein mixture was added to a Ni-NTA column pre-equilibrated with 0.1 M potassium 
phosphate buffer (pH 7.4). The column was washed with 5X column volumes of buffer B (0.1 
M potassium phosphate pH 7.4, 0.1 M NaCl) containing 20 mM Histidine. The monomeric 
protein: MSP (-) fractions were then eluted using buffer B containing 100 mM Histidine, 
thus effectively separating empty Nanodiscs from the CYP5A1-Nanodiscs. This sample was 
then subjected to size exclusion chromatography using a Superdex 200 10/300 column (GE 
Life Sciences, Piscataway NJ) coupled to a high performance liquid chromatography (HPLC) 
system with an Alliance 2695 analytical separation module (Waters, Milford MA) and a 
Waters 996 photodiode diode array detector (Waters, Milford MA). The Nanodiscs were run 
on the SEC column with an isocratic mobile phase of 0.1 M potassium phosphate buffer at a 
0.5 ml/min flow rate. The Nanodisc peak eluted at approximately 26 minutes. The 
concentrated CYP5A1-ND was stored at -80ºC in the presence of 10% glycerol. 
Characterization of CYP5A1 in Nanodiscs: CYP5A1-Nanodiscs (CYP5A1-ND) were 
characterized using different techniques. SDS-PAGE was used to determine the 
incorporation of CYP5A1 into the Nanodiscs and its purity. The Nanodiscs separated out on 
the PAGE gel as two distinct bands at 56 kD and 23 kD for CYP5A1 and MSP1D1 (-) 
respectively. The purified CYP5A1-Nanodisc constructs were analyzed using UV-visible 
spectra. The construct had a typical peak at 417 nm and the α and β bands (Q-bands) at 536 
nm and 570 nm respectively. The protein was reduced using dithionite in the presence of 
methyl viologen (used at 1/40th of the protein concentration) and the Fe(II) CO spectra was 
measured for all the different constructs as done by Omura and Sato (48) with minor 
modifications. The sample was diluted to a final concentration of 5 μM with buffer A or 
buffer B. Methyl viologen was added at one fortieth the concentration of the protein. This 
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mixture was purged with nitrogen gas for 20 minutes to remove traces of oxygen and 
sodium dithionite was then added anaerobically to reduce the protein. CO-purged 0.1 M 
potassium phosphate buffer was added and the spectrum recorded using a Cary Bio 300 
UV-Vis spectrophotometer (Agilent Technologies, Santa, Clara CA).The CYP5A1-ND were 
further tested by studying the binding to PGH2 substrate analogs 9,11-dideoxy-9α,11α-
epoxymethano Prostaglandin F2α (U44069) and 9,11-dideoxy-9α,11α-methanoepoxy 
Prostaglandin F2α (U46619). 
Activity assay of CYP5A1: Thromboxane Synthase converts PGH2 into TXA2 and also 
forms HHT and MDA as fragmentation products in a separate reaction (49). To test for the 
activity of the recombinant protein, the amount of TXB2 formed was determined using a LC-
MS method (50) along with the formation of HHT and MDA monitored spectroscopically at 
234 nm and 268 nm respectively (51). As PGH2 is very unstable at room temperature and 
degrades fast in aqueous solution, a coupled assay was used to produce PGH2 from COX-2 
(provided by Dr. Michael Malkowski) and arachidonic acid (AA) in the reaction mixture. 50 
nM COX-2 was first reconstituted with 1 µM hematin to produce active COX-2. 50 nM 
CYP5A1 was then added to the reaction mixture and incubated for 2 minutes at 23oC. 5 µM 
arachidonic acid (AA) was added to initiate the reaction and the kinetics of the reaction was 
monitored immediately for 300 seconds at 234 nm corresponding to HHT formation. A 
spectrum was also recorded at the end of the kinetics measurement to determine the 
amount of HHT and MDA formed using their respective extinction coefficients of 33 mM–1 
cm–1 and 31.5 mM–1 cm–1. The reaction was terminated by the addition of 300 µL ice cold 
ethyl acetate. The internal standard PGB2 was added at this point and the reaction mixture 
was shaken for a few minutes. It was then centrifuged at 3000 rpm for 5 minutes to 
separate the organic and aqueous phases. The organic solvent was then extracted and 
evaporated to dissolve the resultant residue in 100 µL of ice cold 40% acetonitrile: 60% 
water. This sample was analyzed for quantitation of TXB2 using liquid chromatography-
tandem mass spectrometry (LC/MS/MS) method with prostaglandin B2 (PGB2) as an internal 
standard. Saturating concentrations of the substrate (arachidonic acid) was used to 
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calculate the reaction Vmax (nmol/min/nmol of CYP) for CYP5A1 activity. Rates are reported 
as the mean ± SE. 
Liquid chromatography- tandem mass spectrometry for quantitation of TXB2: Liquid 
chromatography-tandem mass spectrometry (LC/MS/MS) was employed for quantitation of 
TXB2, and PGB2 parent ions [M + H] + and their corresponding fragment ions. The LC/MS/MS 
system consisted of a Waters Alliance 2795 analytical high performance liquid 
chromatography separation module (Waters, Milford, MA) coupled to an electrospray 
ionization mass spectrometer (Waters Quattro Ultima, Waters, Milford, MA) operated in 
positive mode.  The sample was analyzed using a reversed-phase C18, 1.3 Å, 2.1 mm x 20 
mm and 2.5 µm pore size column (Waters, Milford, MA). The MRM data acquisition 
consisted of monitoring the following analytes in positive mode using these transitions 
(parent ion → fragment ion, cone voltage, collision voltage): PGB2 (333.3 → 175, 30 eV, 20 
eV and 333.3 → 235, 35 eV, 20 eV) and TXB2 (369.3 → 169, 25 eV, 18 eV and 369.3 → 195, 
25 eV, 14 eV) all with 100 ms dwell time. Quantitation of TXB2 was determined using the 
peak areas normalized to the internal standard (PGB2 100 ng/ml) from a previously 
calculated standard curve. Analytical data was processed using Waters Mass Lynx software 
(version 4.1).  
Redox potential measurements: The oxidation reduction potentials of the protein were 
determined photochemically by reductive titrations (52-55). The protein was used in a 3 µM 
concentration with 10 mM EDTA, 0.5 µM Safranin T and 20 nM methyl viologen. A 300 
Watts halogen lamp was used to photoreduce the protein and dye system. The absorbance 
was recorded after irradiating the cuvette for varying lengths of time. Safranin T with an 
Em= -289 mV was used as the indicator dye so that the estimated redox potential difference 
between the protein and dye would be less than 60 mV. The sample was purged with 
ultrapure nitrogen for 20 minutes prior to irradiation. The final reduced state was reached 
by adding sodium dithionite and the data was analyzed according to the Nernst equation.  
The potential of the dye at each point in the titration is given by the Nernst equation:  
ED = EOD + RT/nF log10(fox-Dye/fred-dye) for Safranin T (Equation 1). 
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Assuming that the reaction reaches equilibrium after each titration, the ED of the dye 
equals that of the protein:  
ED = EOP + RT/nF log10(f ox-P/f red-P) (Equation 2) 
Where R stands for the Universal gas constant, T for temperature in Kelvin, n for the 
number of electrons transferred, F for Faraday’s constant, fox-P/fred-P fraction of oxidized 
protein to reduced protein and fox-Dye/fred-dye fraction of oxidized dye to reduced dye. 
The data was fit to multiple wavelengths for the protein and dye using a MATLAB 
subroutine given in the supplementary material. The log plot of the fraction of oxidized to 
reduced protein versus the ED of safranin T gives a straight line. The percentage reduced 
protein to the ED of dye was fit to the Nernst curve using the equation % R = 100/ (1+10^ 
((ED-Eop)/0.59) where % R is the percentage of reduced protein, ED is the equilibrium 
potential of the solution determined by monitoring the dye redox state, EOP is the midpoint 
reduction potential of the protein. The redox potentials were also verified by an oxidative 
titration where dithionite was used to reduce the protein completely in the first step and 
potassium ferricyanide was then used to oxidize the sample back to its oxidized state in the 
presence of the dye. This experiment was repeated for substrate free and both the 
substrate analogs bound to CYP5A1.  
Equilibrium constant determination for cyanide binding to the protein active site: The 
dissociation constants of cyanide binding to substrate free and substrate analog bound 
CYP5A1 were determined by steady state binding measurements. Determination of the 
equilibrium constants was done by titrating ~2 μM protein with increasing concentrations of 
cyanide until saturation was reached. The spectrum of the solution was recorded after each 
cyanide addition. The steady state binding experiment was performed separately with 
substrate free and substrate analogs U44069 and U46619 bound protein. The difference 
spectra obtained was used to calculate the dissociation constant KD of cyanide binding to 
the protein in the substrate free and substrate bound state. The binding data was fitted to 
one site binding hyperbolic equation. 
ΔA446-415nm = ΔAmax[S] / (KD + [S]) (Equation 3) 
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Where ΔA446-415nm is the difference in the maximum and minimum values of the absolute 
difference spectra, [S] is the cyanide concentration and KD is the dissociation constant of 
cyanide binding to CYP5A1.  
Transient state kinetics of cyanide binding to protein active site measured using 
stopped-flow: The rate of cyanide binding to CYP5A1 active site in the presence and absence 
of substrate analogs were determined using the Applied Photophysics SX.18MV stopped 
flow spectrophotometer where CYP5A1 substrate bound and free was loaded into syringe 1 
and syringe 2 contained cyanide with the same concentration of substrate as syringe 1. 
Protein concentrations used were typically ~2 μM. Observed rate constants were 
determined at a minimum of three different substrate concentrations with increasing 
concentrations of substrate analogs U44069 and U46619 (0, 15 µM, 35 µM) added to the 
protein.  In the syringe 2, a high concentration of cyanide (40 mM) was used in order to 
ensure pseudo first order binding kinetics. The solutions in both the syringes were allowed 
to mix with an instrument dead time of 750 ms and the data were obtained on a logarithmic 
scale for 5s. The ∆A447–415nm was calculated from the difference spectra for all the time 
points for each sample and the data was fit to a double exponential equation using Origin 
Pro 8.6.  
∆A447–415nm = A0 + A1e xk1 + A2exk2 (Equation 4) 
Where A1 and A2 are the amplitudes of the fast and slow phases of the reaction respectively 
and k1 and k2 are the rates of fast and slow phases of binding to the protein which are 
determined from the fitting the data obtained to equation 4. 
 
2.5 Results 
Expression and purification: The first construct made with the MALLAVF sequence in 
place of the first 1-29 truncated amino acids produced a very low yield of 0.1mg/L of 
protein, which is considered very low for protein analysis. A second construct was made in 
an attempt to increase the yield of the protein expressed. As described in the materials and 
methods section, a hydrophilic sequence was used, which dramatically increased the yield 
of the protein to ~1mg/L.  
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The purification protocol was also modified at each step to optimize the yield. The 
protein has a characteristic reddish brown color due to the heme moiety. The soret of the 
protein is at 417 nm, as with most of the proteins in the Cytochrome P450 superfamily. 
These have been used in the optimization steps described below as a test for characterizing 
the protein. 
Elution: Imidazole was initially used to elute the bound protein from the Ni-NTA column. 
The reddish brown color of the solubilized protein was dramatically reduced after 
purification through the column. Upon troubleshooting, it was found that the imidazole 
used to elute the protein in fact bound to it. Hence making it unfit for any further assay 
reactions. Thus, 50mM Histidine was used for the consequent procedures.  
Solubilizing detergent: The solubilizing agent used initially was Triton. The protein was 
then substrate bound and analyzed using a UV-Vis spectrophotometer. The spectra showed 
the protein to be in a bound state and it was suspected that triton was the one bound to it. 
Therefore, another detergent Lubrol PX was used for solubilizing. 
Column chromatography buffers:  The column buffers were also then changed 
accordingly to reduce the amount of detergent used during column chromatography [1]. All 
the optimization steps performed are listed in Table 2.1. The yields obtained with different 
purification protocols are shown in a graph in Figure 2.1. 
Nanodisc incorporation:  
Phospholipid analysis: POPC lipid stocks were made to incorporate the CYP5A1 protein 
into Nanodiscs. Phosphate analysis using a phosphate standard was performed to obtain 
the Nanodisc concentration from the lipid stocks. The average concentration of the lipid 
stocks was calculated as 101.58 nmoles/µL. Empty Nanodiscs were then prepared as a 
result of the positive and consistent concentrations. The symmetrical peak was obtained at 
the expected time of 26.75 minutes. 
Membrane Scaffold Protein: In all of the experiments with Nanodiscs, the membrane 
scaffold protein, MSP1D1 was used. These proteins have been derived from the Human 
Apolipoprotein A1 sequence. These proteins contain a TEV cleavage site and a His tag, and 
these proteins hold the lipid bilayer together. 
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Protein incorporation into Nanodiscs: The first construct showed incorporation into 
Nanodisc structures but had low efficiency due to aggregated state of the protein. To 
disaggregate the protein, different detergents like CHAPS, Tween 20 were used and it was 
found that Lubrol had a better efficiency in terms of disaggregating the protein. Another 
method of decreasing the hydrophobic character of the protein was used, which replaced 
the N terminus first 1-29 amino acids with the construct MAKKTSS rather than the MALLAVF 
previously used, as described in the sections above. Along with a dramatic increase in yield 
of the protein expression, this modification also resulted in better Nanodisc incorporation. 
The protein aggregate peak seen at 15 minutes, is much less pronounced than with the first 
construct. The N-terminal truncation of the protein might be postulated to decrease the 
stability of the Nanodisc due to the protein not being able to stay in the disc for long 
periods of time. Therefore collected Nanodisc peaks were re injected after a period of 1 
week to monitor the stability of the Nanodiscs, and the Nanodiscs were seen to be stable 
over this period of time. 
A corresponding protein peak at 417 nm was seen for the Nanodisc peak at 25.40 
minutes. . Figures 2.2A and B show the SDS-PAGE and HPLC chromatogram which 
demonstrate the successful incorporation of purified homogenous and monomeric CYP5A1 
into Nanodiscs. The soret of the Nanodisc incorporated CYP5A1 was also seen at 417 nm. 
These CYP5A1-Nanodiscs were also stable as seen by HPLC chromatograms (data not 
shown) and were tested for the characteristic feature of cytochrome P450s to bind to CO in 
the ferrous state. Figure 2.3 shows the Fe (II)-CO spectra of CYP5A1-Nanodiscs which has a 
prominent peak at 450 nm. 
Activity assay:  
CYP5A1- COX-2 coupled activity assay in membrane bilayers: A coupled activity assay 
was used to measure the activity of CYP5A1-Nanodiscs (56). Briefly, COX-2 with hemin was 
mixed with CYP5A1-Nanodiscs. Arachidonic acid was added to initiate the reaction. PGH2 
was therefore generated in situ due to the reaction between heme reconstituted COX-2 and 
arachidonic acid. The PGH2 formed in this reaction was utilized as a substrate by CYP5A1, 
which in turn converted it into TXA2, MDA and HHT (Figure 2.4) (57). We monitored the 
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three products formed using different methods. HHT and MDA formation were monitored 
using UV-Vis spectroscopy at wavelengths 234 nm and 268 nm respectively. The amount of 
TXB2 formed was determined by a modified LC/MS/MS method as described in the 
materials and methods section. The rate and amount of formation of HHT, MDA and TXB2 
was monitored over a period of 10 minutes by different methods.  
CYP5A1 enhanced activity in membranes: The rate of product formation 
(product/min/mg) of HHT, MDA and TXB2 in detergent solubilized CYP5A1 and in Nanodisc 
are given in Figure 2.5. The values for HHT and MDA fall within the range of previously 
obtained rates (46, 51, 58). In coupled assay, HHT is increased in Nanodiscs ratio by 20% 
(ratio 1.2 ± 0.3), MDA by 60% (ratio is 1.6 ± 0.3) and TXB2 by 130% (ratio 2.3 ± 0.3). The 
increased activity of CYP5A1 in Nanodisc may be the result of several factors described 
below.  
Firstly, the native lipid bilayer environment of the Nanodisc for the proteins CYP5A1 and 
COX-2 might lead to an increase in conformational stability which in turn leads to increases 
in the expected product formation. In fact COX-2 oxygenase activity goes up by 20% when it 
is incorporated into Nanodiscs (unpublished data). As this is a coupled activity assay, the 
increase in activity from both COX-2 and CYP5A1 can synergistically contribute to the 
increase in product formation. Moreover, PGH2 is an unstable hydrophobic molecule. 
Hence, it is possible that the presence of the lipid bilayers of Nanodiscs facilitates the 
effective shuttling of PGH2 from COX-2 to CYP5A1 before PGH2 denatures in aqueous 
solution.   
Secondly, it is probable that the electrostatic environment of the membrane modulates 
the CYP5A1 active site to thermodynamically stabilize the intermediate formed during PGH2 
isomerization and therefore favors the formation of the expected products. Previously, we 
have shown that the electrostatics of the membrane environment can modulate the redox 
potential of cytochrome P450 reductase (CPR) in such a way that it promotes the effective 
electron transfer from CPR to CYP3A4 in membranes (39). Hence we measured the redox 
potential of CYP5A1 in membranes in the presence of different substrates to understand 
the electrostatic modulation of the active site of CYP5A1 by the membrane environment.   
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Thirdly, we speculate that CYP5A1 adopts a more native-like conformation in 
membranes as compared to detergent solubilized state therefore we also measure the 
direct activity of CYP5A1 using synthesized PGH2 in detergents and lipid bilayers. In this 
direct assay of addition of PGH2, HHT is decreased in Nanodiscs by 30% (ratio 0.7), MDA by 
30% (ratio is 0.71) and TXB2 increases by 30% (ratio 1.3 ± 0.3).  
CYP5A1, direct PGH2 assay: To observe the extent of membrane effects purely due to 
the membrane, on CYP5A1, PGH2 was directly added to CYP5A1 in another type of activity 
assay.  
The results from these experiments were similar to those from the coupled activity 
assay. The physiological product of the reaction, TXB2 was again seen to be 100% greater in 
Nanodiscs than in the detergent solubilized system. The amount of HHT and MDA formed 
was interestingly lower in Nanodiscs than in the soluble system, though the HHT and MDA 
ratios remained to be 1:1 in both the cases (Figure 2.6). From these experiments it can be 
seen that CYP5A1 in Nanodiscs produces a greater amount of its physiologically relevant 
product TXB2, and less of its side or fragmentation products. The enzyme is more efficient 
and has a greater turnover number when it is incorporated into a native like membrane 
environment. 
Substrate Binding: CYP5A1-Nanodiscs were also tested for their substrate binding 
properties. CYP5A1 is expressed in platelets and binds specifically to PGH2 (59). As PGH2 is 
labile in aqueous solution, most studies on substrate coordination to the active site are 
studied using two substrate analogs, U44069 (where the C-11 oxygen atom of the PGH2 
analog is replaced by a methyl group) and U46619 (where C-9 oxygen of the PGH2 analog is 
replaced by a methyl group). Previous studies have shown the coordination of CYP5A1 to 
U44069 is in a six coordinate low spin state as seen by UV-Vis spectroscopy while the 
coordination with U46619 is in a six-coordinate low spin state contrary to the five 
coordinate high spin state seen spectrally (23). These analogs were used to discern 
substrate binding characteristics of the active site. The binding of U44069 to CYP5A1 
showed its characteristic trough and peak at 426 nm and 409 nm respectively (Figure 2.7A) 
(17). The spectral shift produced by U44069 shows that the -O- atom (at C9 position) of the 
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molecule binds to the heme active site. The binding of U46619 showed a trough and peak at 
418 nm and 395 nm respectively (Figure 2.7B) (17).  U46619 produces a typical spectra 
characteristic of a high spin state where the -CH2- group (at C9 position) faces the heme 
active site of CYP5A1. PGH2 (the native substrate) shows spectral characteristics similar to 
U44069, which is indicative of binding of an endoperoxide to the active site (18). The 
binding of these two substrates fit to a one site binding hyperbolic equation and the 
spectral dissociation constant of U44069 and U46619 binding to CYP5A1-Nanodiscs were 
determined to be 6 µM and 5 µM respectively. The binding of U44069 is found to be tighter 
in Nanodiscs compared to 14 µM in detergents.   
Redox potentials: To probe the electrostatics around the heme active site in CYP5A1, 
we measured the redox potentials of the substrate free and substrate analogs bound 
CYP5A1. As shown in figure 2.8, the substrate free redox potential of CYP5A1 is -282 ± 2 mV. 
This value is slightly more positive than the usual values obtained for soluble P450s or 
detergent solubilized P450s (54, 60). The addition of its native substrate analog U44069 
resulted in an EM of -284.5 ± 0.5 mV (Figure 2.9) while the binding of the other substrate 
analog U46619 produced a small positive shift to -270 ± 5 mV (Figure 2.10). Considering that 
the error range of these measurements was ±5 mV, there was not a significant change in 
the redox potentials on binding either substrate. The substitution of the water at the active 
site by the endoperoxide oxygen of U44069, does not change the redox potential while the 
addition of U46619 where the methyl group binds close to the heme center is accompanied 
by a redox potential change of ~ +10 mV. The spin state change on binding U46619 was ~ 
14% and hence we do not expect a dramatic redox potential change as these two 
parameters have been shown to be linked for both soluble and membrane bound proteins 
(60, 61).  
Different mechanisms have been proposed to explain the formation of these three 
products. Ullrich and Hecker (Ref) postulated the formation of an Fe(IV)-porphyrin 
intermediate and density functional theory (DFT) studies by Yanai and Mori (62) proposed 
that CYP5A1 may also isomerize PGH2 via the Fe(III)-porphyrin π-cation radical intermediate. 
In both pathways the reaction proceeds through homolytic cleavage of the endoperoxide O-
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O bond of PGH2 to give an alkoxy radical. This first step of binding of the endoperoxide to 
CYP5A1 has been shown to have the highest activation energy (63). Additionally, unlike 
most classical cytochrome P450s, the addition of native substrate PGH2 to CYP5A1 does not 
convert the Fe(III) of CYP5A1 into a high spin complex (58). This is due to the epidioxy ligand 
(PGH2), being a weak field ligand that replaces water as a ligand at the sixth coordination 
center. In either of the two cases mentioned above, stabilization of the higher redox state 
Fe (IV) for the substrate bound protein might be correlated with the higher activity of 
CYP5A1 with respect to its ability to isomerize PGH2. In other words, CYP5A1 bound to 
substrate is less likely to be reduced and therefore its redox potential (tendency to get 
reduced) should be lower. This was shown to be true as binding of both U44069 and 
U46619 to CYP5A1 did not change the redox potential considerably when compared to 
substrate binding in other systems. 
In order to understand the role of membranes in modulating the redox potential of 
CYP5A1, we also measured the redox potential of substrate free, U44069 bound and 
U46619 bound CYP5A1 in a detergent solubilized state. CYP5A1 when substrate free gave a 
redox potential of -300 ± 10 mV. The redox potentials of U44069 bound CYP5A1 was 
measured to be -318 ± 10 mV and that of U46619 bound was -307 ± 10 mV in detergent 
(Figure 2.11). This is opposite to the trend seen in Nanodiscs towards less negative midpoint 
potentials upon addition of substrate. Overall all the redox potentials are close to each 
other. So it is possible that the membranes are not modulating the redox potential of 
CYP5A1 to facilitate the stabilization of its PGH2 bound intermediate. Therefore we 
conclude that this modest modulation of the redox potential of CYP5A1 cannot possibly 
account for the 100% increase in CYP5A1 catalyzed activity. The structure of CYP5A1 was 
modeled in Phyre2 (64) and this was used to obtain the orientation of CYP5A1 in 
membrane. The resultant model structure of CYP5A1 in membranes shows that the protein 
in not deeply embedded in the membrane (Figure 11). Therefore, the active site would be 
further away from the lipid bilayer and would not be influenced substantially by the 
electrostatics of the membrane.  
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Cyanide binding: The protein may adopt a different conformation in Nanodisc as 
compared to its state in solution, leading to the observed increase in product formation. In 
order to explore the active site accessibility, we measured the access of cyanide to the ferric 
state of CYP5A1 is its substrate and bound form. In this case the rate of cyanide binding was 
measured as a function of substrate analog concentration to probe how substrate binding 
blocks the cyanide access to the active site (65).  
Equilibrium cyanide binding studies to CYP5A1: We measured the equilibrium KD of 
cyanide binding to the protein in the presence and absence of a substrate. U44069 is a 
substrate analog of PGH2 and is not metabolized by CYP5A1 but is an excellent model 
compound to study how PGH2 binds to the heme center. CYP5A1 in Nanodiscs bound to 
U44069 has a dissociation constant of 6 µM, in contrast to 15 µM in detergent solubilized 
systems. This shows that the binding of the substrate analog is more than two fold tighter in 
Nanodiscs than previously reported in other systems.   
Equilibrium cyanide binding studies to CYP5A1 were performed at 6oC to probe the 
active site accessibility. The dissociation constant KD determined for cyanide binding to 
substrate free CYP5A1 in Nanodiscs is 12 mM and that of U44069 bound CYP5A1 in 
Nanodiscs is 37 mM and U46619 bound is 17 mM. For detergent solubilized CYP5A1, the KD 
of cyanide binding values changed from 18 mM for substrate free to 28 mM for U44069 
bound CYP5A1 and 22 mM for U46619 bound CYP5A1.  The substrates were added at 
saturating levels to both the systems (~60 µM). As shown in Table 2.2, this is a dramatic 
increase in the KD of binding for CYP5A1-Nanodisc when compared to similar systems 
studied earlier. The effect is more pronounced in Nanodiscs indicating that the 
conformation of the substrate binding pocket in CYP5A1-Nanodiscs changes dramatically 
upon substrate binding, which might hinder the active site access to cyanide binding. 
Therefore, the KD of cyanide binding to U44069 bound CYP5A1 in Nanodiscs is higher 
comparatively. An alternative hypothesis is that cyanide binding has easy access in 
substrate free CYP5A1 in both detergent and Nanodiscs, but the substrate binding pocket is 
narrower in Nanodiscs when blocked by substrate, leading to a lower KD of cyanide binding 
as seen in some other systems (65-67).  
29 
 
To investigate the dynamics of the active site conformation upon substrate binding, the 
cyanide binding experiments were conducted with another substrate analog, U46619. As 
previously mentioned, U46619 has a C (11) substitution instead of an oxygen atom. There 
have been discrepancies in literature as to how PGH2 binds to the heme iron. Many theories 
suggest that PGH2 binds using both the O (9) and the O (11) atoms though it preferentially 
uses an O (9) binding to the Fe (68). The KD of cyanide binding to CYP5A1 with U46619 
bound in Nanodiscs is 17 mM and in detergent is 22 mM which is similar to the 12 mM and 
18 mM values respectively in substrate free CYP5A1. As it can be clearly seen from this data, 
U46619 hinders the binding of cyanide in Nanodiscs to a lower extent than does U44069. 
Kinetics of cyanide binding to CYP5A1 - amplitude of fast phase: We further measured 
the rate of cyanide binding to CYP5A1 in the presence and absence of substrates similar to 
the equilibrium state measurements. The data for the kinetics of cyanide binding fit to a 
double exponential equation. The first phase of the reaction is defined as the fast phase 
that is related to the association of cyanide to the active site. It is speculated that the 
second or slow phase is correlated to the slow conformational change that exists between 
different states of the protein (69). Figure 2.12D and E shows the percentage of amplitude 
in the fast phase of the cyanide binding to CYP5A1 with both the substrate analogs. In 
CYP5A1-Nanodiscs, when bound to U44069, we observed a dramatic decrease in the 
percentage fast phase from 72% at substrate free to 33% when saturating amounts of 
substrate is present. Interestingly, in detergent solubilized system, there is not much 
variation in this fast phase amplitude as it stays constant around ~50%. This is an indication 
that the conformation adopted in membrane bilayer allows U44069 to block the active site, 
which prevents rapid cyanide binding. The kinetics data agrees with our equilibrium binding 
data, that the KD of binding increases when U44069 binds to CYP5A1 in Nanodiscs.  
The trend for the other substrate U46619 is not significantly different in solution when 
compared to membranes. Interestingly, the detergent system shows a much greater 
variation from 78% at substrate free to 18% at saturating concentration of U46619. The fast 
phase amplitude of the Nanodisc system changes from 66% at substrate free to 40% at 
saturating concentration of substrate. However, the binding of U46619 is not very different 
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in the soluble and membrane systems. The rates of cyanide association calculated for both 
the fast and slow phases of the reaction at increasing concentrations of U44069 and 
U46619 are shown in Figures 2.12F and G respectively.  
Kinetics of cyanide binding to CYP5A1- rates of association: The slow phase rate of all 
the systems with any concentration of substrate bound, is very similar. There are however 
multiple differences in the association rate during fast phase (Figure 2.12F and G). In 
CYP5A1-Nanodiscs, the rate of association in the fast phase for U44069 decreases as the 
concentration of substrate is increased, while in detergent solution, it remains constant. 
This is very similar to the trend observed for the percentage of amplitude in the fast phase 
as discussed in the above section. For the binding of U46619, the trend in closing off the 
active site to cyanide binding appears to be absent in both detergents and Nanodisc 
systems, as there is no significant difference in their fast phase rates of association.  
It is clear from the cyanide accessibility studies that the protein adopts a different 
conformation state in lipid bilayer membranes. The binding of U44069 (the native-like 
substrate) reduces the accessibility of cyanide to the active site.  Therefore it is highly 
probable that the increase in the isomerization of PGH2 into TXB2, MDA and HHT by 
CYP5A1-Nanodiscs can be attributed to the change in conformation of the CYP5A1 in 
Nanodiscs and not from electrostatic modulation by the membrane. 
 
2.6 Conclusion 
The thermodynamics and kinetics of substrate analog binding to CYP5A1 in model lipid 
bilayer Nanodiscs was elucidated in this work. The coupled activity of CYP5A1 with COX-2 in 
membranes was measured, which was shown to be enhanced in lipid bilayers by 130% for 
TXB2 formation. The increase in activity is attributed to several possible factors and different 
techniques were further employed to study some of the factors.  
In the Nanodisc lipid membrane environment, both CYP5A1 and COX-2 presumably 
adopt more native-like conformations. We believe that this stabilizing effect of the 
membrane environment leads to the increase in product formation. In a separate work, it 
was established that COX-2 oxygenase activity increases by ~20-30% in Nanodiscs 
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(unpublished data). As this is a coupled activity assay, the increase in activity can be 
ascribed to the synergistic action of both COX-2 and CYP5A1 in membranes, leading to the 
increase in the amount of products formed. To gauge the effect of membranes on CYP5A1 
alone, a direct activity assay was used with CYP5A1. It was seen that the TXB2 formation 
increased by a mere 30% compared to the 130% in the coupled assay. The incorporation of 
COX-2 and CYP5A1 in membranes, accounts for only a part of the increased TXB2 formation, 
seen in the coupled assay. Another possible mechanism which accounts for the dramatic 
increase seen in the coupled assay is an effective shuttling of the substrate PGH2 through 
the membrane. Eicosanoids generated in the prostanoid synthesis pathway are partially 
hydrophobic and very labile in aqueous solution. Therefore the presence of the membrane 
environment possibly aids in shuttling the COX-2 product PGH2, through the membrane, to 
CYP5A1 in Nanodiscs.  
It was shown in a previous study, that the electrostatic modulation of the active site in 
Cytochrome P450 Reductase (CPR), can lead to higher stability of active intermediates 
formed in the reaction, which increases the product generation. Hence the redox potential 
of CYP5A1 in the presence of different substrates in reconstituted system and in 
membranes was measured, to understand the electrostatic modulation of the active site of 
CYP5A1 by the membrane environment.  The redox potential of substrate free and 
substrate bound CYP5A1-Nanodisc were ~20mV more positive than the detergent 
solubilized state. This change in redox potential is very low and does not account for the 
dramatic increase seen in product formation.   
CYP5A1 interacts with the membrane both through the amino-terminal membrane-
anchoring domain and the helix F and F–G loop region. When the N-terminus is truncated 
and residues in the F and G helices are substituted, a soluble CYP5A1 protein can be 
engineered. As CYP5A1 is embedded in the membrane in its native state, it is important to 
understand if the membrane induces CYP5A1 to a different conformation, which might play 
a role in enhancing the activity of CYP5A1. The equilibrium steady state cyanide binding to 
CYP5A1 bound to native-like substrate U44069 and to U46619 was measured. The binding 
of U44069 is tighter and binding of cyanide is inhibited to a greater extent, especially when  
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in Nanodiscs. This is also evident from the kinetics of cyanide binding as shown in sections 
above. Therefore, from these experiments we propose that there is a substantial 
conformational change in the CYP5A1 when incorporated into Nanodiscs that may explain 
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Figure 1.1 Prostaglandin pathway from Arachidonic acid 
 






Table 2.1. Optimization conditions for CYP5A1 purification protocol 
Step Batch 0 Batch 1 Batch 2 Batch 3 
Inoculation of 
primary culture  
From plate From plate From stock From stock 
Media for 
primary culture 





























0.5mM δ- ALA, 
4g Arabinose 
1.0mM IPTG, 




27oC 27oC 27oC 27oC 
Induction RPM 160 RPM 160 RPM 160 RPM 160 RPM 
Resuspension 
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Dnase, Rnase No No Yes Yes 
Sonication 5X, 80% Duty 
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Figure 2.2. Characterization of CYP5A1-Nanodiscs. (A) CYP5A1 was incorporated into Nanodiscs 
and purified using size exclusion chromatography-HPLC. SDS-PAGE was used to verify the 
isolation of CYP5A1-Nanodiscs. Column 2 shows the protein molecular weight standards and 
column 1 shows two bands that corresponds to ~56 kDa for CYP5A1 and ~24 kDa corresponds 
to the molecular weight of MSP1D1(-). (B) Size exclusion HPLC chromatogram of CYP5A1 in 







Figure 2.3. CO-Binding difference spectrum of CYP5A1 in Nanodiscs. The protein in Nanodiscs 






















Figure 2.5. (Left) Schematic of COX-2 docking on the membrane bilayers of CYP5A1-Nanodiscs 
and PGH2 shuttling through the membrane. (Right) Coupled Activity measurement of CYP5A1 in 
aqueous solution and in Nanodiscs. CYP5A1 converts PGH2 into MDA, HHT and TXB2 in a 
coupled assay where PGH2 is formed in situ from arachidonic acid (AA) via COX-2.  The amount 
of HHT and MDA formed were measured using UV-Vis spectroscopy while TXB2 formation was 
measured using LC/MS/MS. The relative amount of HHT, MDA and TXB2 formed in CYP5A1-
Nanodisc is higher than the amount formed by CYP5A1 in aqueous solution. Moreover, the rate 
of formation of both HHT and MDA is higher for CYP5A1 Nanodiscs compared to CYP5A1 in 
aqueous solution. The HHT formed is 20% higher, MDA is 60% higher and the TXB2 formed is 










Figure 2.6. Activity measurement by direct PGH2 addition of CYP5A1 in aqueous solution and in 
Nanodiscs. The amount of HHT and MDA formed were measured as described previously. The 
relative amount of HHT and MDA formed in CYP5A1-Nanodisc is surprisingly 33% lower than 
the amount formed by CYP5A1 in aqueous solution, but the TXB2 formed remains 100% higher 

















































































Figure 2.7: (A) Steady state binding of U44069 to CYP5A1-Nanodiscs. The KD is determined to be 
6 µM in Nanodiscs and 15 µM in detergent solubilized state (Inset: Difference spectrum of 
U44069 bound CYP5A1-Nanodiscs) (B) Steady state binding of U46619 to CYP5A1-Nanodiscs. 
The KD is determined to be 5µM (Inset: Difference spectrum of U46619 bound CYP5A1: ND) 
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Figure 2.8: The redox titration of CYP5A1 in Nanodiscs is conducted in 100 mM phosphate buffer 
pH 7.4 at 25°C for substrate free. The change in the absorption maxima on light reduction were 
used to calculate the percentage of reduced protein. The potential is measured using safranin T 
dye based method using light based reduction as well as dithionite based reduction. The Nernst 
plot (25° C) for single electron redox function is reported for the substrate free CYP5A1 and 
substrate bound forms. The zero intercept gives E°′, the redox potential of the protein and the 
slope divided by 59 mV yields n, the number of electrons involved in the reaction which is 0.8 – 
1 for the measurements indicated. This figure corresponds to the redox titration of CYP5A1 in 
Nanodiscs in substrate free and substrate bound state. The redox potential of the substrate 
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Figure 2.9: The redox titration of CYP5A1 in Nanodiscs is conducted in 100 mM phosphate buffer 
pH 7.4 at 25°C for 60 µM substrate U44069 bound protein. The redox potential of the substrate 
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Figure 2.10: The redox titration of CYP5A1 in Nanodiscs is conducted in 100 mM phosphate 
buffer pH 7.4 at 25°C for 60 µM substrate U46619) bound protein. The redox potential of the 
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Figure 2.11: The redox titration of CYP5A1 in solubilized system at pH 7.4 at 25°C for substrate 
free and 60 µM substrate (U44069 or U46619) bound protein. The same method as used for 
CYP5A1 ND was used. (A) (B) (C) corresponds to the redox titration of CYP5A1 in Nanodiscs in 
substrate free and substrate bound state. The redox potential of the substrate free CYP5A1 is -




 Kd (mM) Reference 
5A1, substrate free 14 This work 
5A1, U44069 24 This work 
5A1, U46619 16 This work 
5A1:ND, Substrate free 11.6 This work 
5A1:ND, U44069 37 This work 
5A1:ND, U46619 22 This work 
CYP3A4, substrate free 0.4 (66) 
CYP3A4, TS 1.4 (66) 
CYP101, Substrate free 0.12 (67) 
CYP101, substrate 4.7 (67) 
eNOS, Substrate free 5.6 (70) 
eNOS, substrate 40 (70) 
 




Figure 2.12. Cyanide binding to substrate free and substrate bound CYP5A1 in detergents and in 
Nanodiscs. (A) UV-Vis spectra of steady state binding titration of cyanide to CYP5A1 in 
Nanodiscs. (B) Difference spectra of data shown in figure 3A. (C) The change of absorbance (ΔA) 
from 447 nm to 415 nm was calculated for each titration and plotted against the corresponding 
cyanide concentration.  Data was fitted with Origin Lab to the single binding isotherm. (D)  The 
percentage of amplitude in the fast phase of the rate of the cyanide binding to CYP5A1 versus 
increasing concentration of substrate U44069. (E) The percentage of amplitude in the fast 
phase of the rate of the cyanide binding to CYP5A1 versus increasing concentration of substrate 
U46619. Rates of fast and slow phase of cyanide binding to CYP5A1, kfast and kslow versus 
increasing concentrations of substrate are reported for (F) U44069 and (G) U46619. 
(µM) (µM) 
